Skip to main content
PHARPharming Group N.V.Sell6.5·$12.93

Pharming Group (PHAR) Q2 2026 earnings — TrendMatrix coverage

IN LINE-96.8% vs estimateEPS — vs $0.06 estCurrent verdict Sell 6.5/10

Reported

Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure · Editorial policy

Event detail · Q2 2026

Key numbers

Adjusted EPS
—
Estimate
$0.06
Surprise
-96.8%
Revenue (period 2026-06-30)
$90.2M
Score today
6.5/10

Revenue source: yfinance_provisional (provisional — SEC XBRL not yet filed for this period).

Current read · as of 2026-11-04

Where TrendMatrix's rating stands now

TrendMatrix currently rates PHAR Sell at 6.5/10; no pre/post engine snapshot brackets this report.

2 of the last 4 quarters beat the estimate; this quarter's -96.8% surprise compares with a -372.6% four-quarter average.

What supports the rating

  • V7 quality resilience bonus: +0.2 (Q=7.3 in RISK_OFF)
  • Sector modifier (Healthcare): +0.5

What argues against it

  • Euphoria warning: extreme positivity (+1.00) + overbought RSI 84
  • Overbought (RSI 84)
  • Below 200-MA, MA slope -7.0%/30d (confirmed downtrend)

This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.

Current engine read

The levels TrendMatrix's engine tracks

Current price
$12.93
Price target
$29.84
Stop
$12.02
Upside to target
+130.8%
Reward-to-risk
8.7:1

Forward estimates sit below the trailing run-rate (71.8× forward vs 40.4× trailing) — consensus expects earnings to decline from here.

Risk check: RSI 84 — a level conventionally read as overbought; gains at these levels often lean on momentum.

Model outputs from TrendMatrix’s engine as of 2026-11-04 — shown for context, not personalized investment advice.

Healthcare context

PHAR at TrendMatrix's latest read

Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.

Industry
Biotechnology
Market cap
$915.2M
P/E (fwd)
71.8
P/E (ttm)
40.4
52-week range
$9.11–$21.34
Off 52-week high
39.4%
RSI (14)
84
Volume vs avg
1.41×
Score today
6.5/10

EPS and the estimate come from Yahoo Finance’s earnings calendar, captured around the report date. That EPS is the adjusted figure analysts forecast, so it can differ from the GAAP diluted EPS in the company’s filing, and consensus estimates vary between data providers. Revenue comes from SEC XBRL company facts where available, yfinance-provisional otherwise. Not a buy/sell rating, a price target, or investment advice — see the current verdict on the stock’s main page for TrendMatrix’s live read.

Home › Stocks › PHAR › Earnings › Q2 2026 earnings